Reinforcement learning for causal discovery and data quality monitoring

00

000

 (\cap)

Funded by Hoffman la Roche

CERN OpenLab technical Workshop

Olivia Jullian Parra (CERN, Geneva) Sara Zoccheddu (University of Zurich, Zurich) Shah Rukh Qasim (University of Zurich, Zurich) Julián García Pardiñas (CERN, Geneva) Nicola Serra (University of Zurich/CERN, Geneva) Milo Alan Puhan (University of Zurich, Zurich) Henock Yebyo (University of Zurich, Zurich) Maximilian Janisch, (University of Zurich, Zurich) Thomas Lehéricy,(University of Zurich, Zurich)





Index

- Causal Inference Challenge
- 2 Understanding causal inference: causal discovery
- 3 Reinforcement Learning for causal discovery
- Similarities between causal discovery and data quality monitoring techniques
- Reinforcement Learning for data quality monitoring in HEP experiments
- Conclusions and future steps

Causal inference challenge



When studying a treatment for a disease...



4

Causal inference challenge



Machine Learning for causal inference



What CVAE offers

- Extract Z from X,Y,t (p(Z/X,Y,t)): acquire all the data responsible for the outcome Y
- Predict Y (q(Y/Z,X,t)): have counterfactual data to understand how t affects the outcome Y

Proof of concept: statins treatment effect



Results on treatment effect prediction



Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019 Apr;210:18-28. doi: 10.1016/j.ahj.2018.12.007. Epub 2019 Jan 10. PMID: 30716508.

Yebyo, H. G., Günthard, H. F., Rehfuess, E. A., Serra, N., Haile, S. R., Senn, O., ... & Puhan, M. A. Statins for Primary Prevention of Cardiovascular Events in People Living with HIV: A Target Trial and Benefit Harm Balance Modelling Study. Available at SSRN 4427462.

CVAE calibration



Small overestimation of the risk when the treatment is taken

Limitations

Unobserved confounders: what is the real X? Benefit-Harm treatment study Y • What if there are new X X Χ variables to consider for the Χ treatment effect? Χ Χ Χ **Multiple interactions** Χ Χ • What if there are multiple V treatments in place to test? What if the treatment also affects other X variables?

Causal discovery Ŵ

Causal Discovery pipeline



Experiments

ground truth recovered_pruned_graph 0 -0 2 -2 · Node i 4 6 6 8 8 10 10 5 7 10 5 0 0 7 10 2 2

Iteration: 3999

Node j

Toy dataset

- Variables have linear
 - gaussian dependencies

• The variance of the values is the same for all of them

Zhu, S., Ng, I., & Chen, Z. (2019). Causal discovery with reinforcement learning. arXiv preprint arXiv:1906.04477.

Actor-Critic model for RL



Actor

- Takes a state derived from all the observational data
- Works under a policy
- Proposes a causal graph candidate

Critic

- Evaluates the graphs proposed by the actor
- Predicts again the obs. data using the graph proposed (needs optimization)

Environment

- Representation of the observational data collection
- Represents all the possible patient variables, treatments and outcomes

Data quality monitoring



Systems are imperfect and may bias the collected data.



When the system status is incorrectly classified as good, measurements are biased.



When the system status is incorrectly classified as bad, data collection efficiency reduces.

Reduce bias in the data

Goal

Detect and correct system

errors

Improve data collection efficiency

Actor-Critic model with human feedback



Results



Probability of human failure: 0.3

- We can **achieve superhuman condition** for the offline regime
- How do we know when to rely on the machine?
 We are currently performing studies on the detection of superhuman condition during training, without having access to the ground truth¹

Conclusions





Q&A

olivia.jullian.parra@cern.ch

